Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

Molecular Psychiatry
V S BasileJ L Kennedy

Abstract

Tardive dyskinesia (TD) is a disabling neurological side effect associated with long-term treatment with typical antipsychotics. Family studies and animal models lend evidence for hereditary predisposition to TD. The newer atypical antipsychotics pose a minimal risk for TD which is in part attributed to their ability to block the serotonin-2A (5-HT(2A)) receptor. 5-HT(2A) receptors were also identified in the basal ganglia; a brain region that plays a critical role in antipsychotic-induced movement disorders. We tested the significance of variation in the 5-HT(2A) receptor gene (HTR2A) in relation to the TD phenotype. Three polymorphisms in HTR2A, one silent (C102T), one that alters the amino acid sequence (his452tyr) and one in the promoter region (A-1437G) were investigated in 136 patients refractory or intolerant to treatment with typical antipsychotics and with a DSM-IIIR diagnosis of schizophrenia. We did not find any significant difference in allele, genotype or haplotype frequencies of polymorphisms in HTR2A among patients with or without TD (P > 0.05). Further analysis using the ANCOVA statistic with a continuous measure of the TD phenotype (Abnormal Involuntary Movement Scale (AIMS) score) found that the AIMS scores we...Continue Reading

References

Oct 21, 1991·Nucleic Acids Research·D K Lahiri, J I Nurnberger
Sep 1, 1988·The British Journal of Psychiatry : the Journal of Mental Science·J L Waddington, H A Youssef
Dec 1, 1981·The American Journal of Psychiatry·R Yassa, J Ananth
Nov 1, 1994·Pharmacology, Biochemistry, and Behavior·H RosengartenA J Friedhoff
Sep 30, 1994·Science·E S Lander, N J Schork
Jan 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·M ArmstrongJ R Idle
Jun 18, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M MasellisJ L Kennedy
May 29, 1999·Critical Reviews in Neurobiology·B L RothK Kristiansen
Jun 24, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·V S BasileJ L Kennedy
Aug 5, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H Y Meltzer
Mar 1, 2000·The Journal of Clinical Psychiatry·Y NeriaA Ohry
Jul 7, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H HoriJ Nakamura

❮ Previous
Next ❯

Citations

Apr 12, 2008·European Archives of Psychiatry and Clinical Neuroscience·Wolfgang Maier, Astrid Zobel
Feb 22, 2011·Current Psychiatry Reports·Nabilah I ChowdhuryJames L Kennedy
Mar 23, 2002·European Journal of Pharmacology·Alessandro SerrettiEnrico Smeraldi
Jun 6, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Osamu OhmoriJun Nakamura
Apr 25, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Hasan HerkenHaluk A Savaş
Feb 16, 2013·Expert Opinion on Investigational Drugs·Tiago A MestreSusan H Fox
Dec 18, 2010·Expert Opinion on Drug Metabolism & Toxicology·Jian-Ping Zhang, Anil K Malhotra
Apr 15, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Piotr M CzerskiJoanna Hauser
Sep 14, 2010·Clinics in Laboratory Medicine·Peter P Zandi, Jennifer T Judy
Sep 14, 2010·Clinics in Laboratory Medicine·Adriana FosterPeter Buckley
Feb 18, 2010·The Psychiatric Clinics of North America·Peter P Zandi, Jennifer T Judy
May 15, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·A F Y Al HadithyA J M Loonen
Aug 28, 2007·The Psychiatric Clinics of North America·Adriana FosterPeter F Buckley
Dec 14, 2004·BMC Medical Genetics·Alessandro Serretti, Enrico Smeraldi
Nov 6, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chul-Hyun Cho, Heon-Jeong Lee
Jul 31, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Behdin NowrouziVincenzo De Luca
Sep 9, 2006·The International Journal of Neuropsychopharmacology·Clement C ZaiJames L Kennedy
Aug 19, 2014·Journal of Neural Transmission·Chiara FabbriAlessandro Serretti
Jan 22, 2008·Schizophrenia Research·Hua JinDilip V Jeste
Jul 30, 2016·Pharmacogenomics·Rachel K LanningDaniel J Müller
Mar 26, 2004·The Pharmacogenomics Journal·D J MüllerJ L Kennedy
Aug 5, 2003·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Swati S RanadeVishwajit L Nimgaonkar
May 16, 2008·Journal of Clinical Psychopharmacology·Enrique López-TorresAdrián Llerena
Oct 16, 2009·Psychiatric Genetics·Ismail Al-JanabiJose de Leon
Jan 13, 2006·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Mary Ann RichardsonRaymond F Suckow
Jun 3, 2014·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Eva J BrandlDaniel J Müller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.